Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
Shiozawa
Kazue
K
Department of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, Tokyo, Japan.
Watanabe
Manabu
M
Takenaka
Hiroki
H
Nagai
Hidenari
H
Ishii
Koji
K
Sakai
Ken
K
Sumino
Yasukiyo
Y
D000142:Acidosis, Respiratory / Q000139:chemically induced; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib